Loading cancer entity…
Loading cancer entity…
Clinical trials
6,746 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
Computedformula ci-trial-intel-v1 · interventional studies · entity + NCIt descendants · hover a figure for its formulaCompare cancersTerminated studies (1,045)
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT06463665 | Efficacy & Safety of Olvimulogene Nanivacirepvec & Platinum-doublet + Physician's Choice of Immune Checkpoint Inhibitor Compared to Docetaxel in NSCL Cancer(VIRO-25) | recruiting | Phase 2 | 142 | Genelux CorporationINDUSTRY | 1 | Jun 4, 2026 | clinicaltrials |
| NCT07234877 | Phase II Study of Upfront SRT Plus Ivonescimab/Chemotherapy vs Ivonescimab/Chemotherapy in NSCLC Brain Mets | not yet recruiting | Phase 2 | 158 | European Organisation for Research and Treatment of Cancer - EORTCNETWORK |
| 8 |
| Jun 4, 2026 |
| clinicaltrials |
| NCT07269782 | A Phase II Study to Evaluate the Efficacy and Safety of HLX43 + Serplulimab as Neoadjuvant Therapy in Subjects With NSCLC | recruiting | Phase 2 | 60 | Shanghai Henlius BiotechINDUSTRY | 1 | Jun 4, 2026 | clinicaltrials |
| NCT07627321 | Becotatug Vedotin Combined With Pucotenlimab ± Radiotherapy as First-Line Treatment for Driver-Gene-Negative, EGFR-Expression-Positive Advanced Non-Small Cell Lung Cancer(PRAD2) | not yet recruiting | Phase 2 | 39 | Anhui Provincial Cancer HospitalOTHER | 1 | Jun 4, 2026 | clinicaltrials |
| NCT05642572 | Comparing Combinations of Targeted Drugs for Advanced Non-Small Cell Lung Cancer That Has EGFR and MET Gene Changes (A Lung-MAP Treatment Trial) | recruiting | Phase 2 | 66 | SWOG Cancer Research NetworkNETWORK | 1 | Jun 3, 2026 | clinicaltrials |
| NCT07622706 | Firmonertinib in Perioperative Treatment of Resectable Stage II-IIIB EGFR-mutated Lung Adenocarcinoma | not yet recruiting | Phase 2 | 60 | Peking University Cancer Hospital & InstituteOTHER | 0 | Jun 3, 2026 | clinicaltrials |
| NCT06731413 | Reduced CT + Anti-PD-1 as First Line Tx in Vulnerable Older Adults w/Adv <50% PD-L1 Non-Small Cell Lung Cancer (NSCLC) | recruiting | Phase 2 | 40 | Virginia Commonwealth UniversityOTHER | 1 | Jun 2, 2026 | clinicaltrials |
| NCT07619911 | SHR-1701 for Induction and Consolidation Therapy in Unresectable Stage III Non-Small Cell Lung Cancer | not yet recruiting | Phase 2 | 84 | Fudan UniversityOTHER | 0 | Jun 2, 2026 | clinicaltrials |
| NCT05633667 | Study of Novel Treatment Combinations in Patients With Lung Cancer(VELOCITY-Lung) | active not recruiting | Phase 2 | 192 | Gilead SciencesINDUSTRY | 8 | Jun 1, 2026 | clinicaltrials |
| NCT05676931 | Study With Various Immunotherapy Treatments in Participants With Lung Cancer(EDGE-Lung) | active not recruiting | Phase 2 | 400 | Gilead SciencesINDUSTRY | 10 | Jun 1, 2026 | clinicaltrials |
| NCT05933239 | Macrophage Imaging Using Ga-MMR-VHH2 in Lung Cancer Patients(MAGMA) | recruiting | Phase 2 | 20 | Universitair Ziekenhuis BrusselOTHER | 1 | Jun 1, 2026 | clinicaltrials |
| NCT07618793 | Intermittent Hypoxic Training as Neoadjuvant Therapy for Lung Squamous Cell Carcinoma | not yet recruiting | Phase 2 | 60 | zhang yiOTHER | 1 | Jun 1, 2026 | clinicaltrials |
| NCT04956640 | Study of LY3537982 in Cancer Patients With a Specific Genetic Mutation (KRAS G12C) | active not recruiting | Phase 1 / Phase 2 | 540 | Eli Lilly and CompanyINDUSTRY | 6 | May 29, 2026 | clinicaltrials |
| NCT06246110 | A Phase 2 Study of EIK1001 in Combo With Pembrolizumab and Chemotherapy in Patients With Stage 4 NSCLC | active not recruiting | Phase 2 | 70 | Eikon TherapeuticsINDUSTRY | 1 | May 28, 2026 | clinicaltrials |
| NCT07223047 | A Study to Evaluate the Safety, Tolerability, and Efficacy of BMS-986523 Alone and in Combination With Anti-Cancer Agents in Participants With Advanced Solid Malignancies | recruiting | Phase 1 / Phase 2 | 252 | Bristol-Myers SquibbINDUSTRY | 3 | May 28, 2026 | clinicaltrials |
| NCT05910827 | A Phase Ib/II Study of an Anti-HER3 Antibody, HMBD-001, With Cetuximab +/- Docetaxel in Advanced Squamous Cell Cancers | recruiting | Phase 1 / Phase 2 | 398 | Hummingbird BioscienceINDUSTRY | 5 | May 27, 2026 | clinicaltrials |
| NCT07609251 | A Clinical Study of SCTB41 Combined With Docetaxel in Patients With Previously Treated Locally Advanced or Metastatic Non-Small Cell Lung Cancer（Phase II Study Ongoing） | not yet recruiting | Phase 2 | 90 | Sinocelltech Ltd.INDUSTRY | 1 | May 27, 2026 | clinicaltrials |
| NCT06974370 | Avoiding Radiation Therapy Due to Intracranial Response to Chemotherapy, Targeted Therapy and/or Immuno-ONcology Therapy for Brain Metastases: Pilot Pragmatic Trial(ACTION-Brain) | recruiting | Phase 2 | 45 | University of Vermont Medical CenterOTHER | 1 | May 26, 2026 | clinicaltrials |
| NCT07249372 | DRP-104 in Patients With NFE2L2/KEAP1-altered Non-Small Cell Lung Cancer | recruiting | Phase 2 | 37 | NYU Langone HealthOTHER | 1 | May 26, 2026 | clinicaltrials |
| NCT07375316 | A ctDNA-guided Phase II Trial of Osimertinib in Combination With Sacituzumab Tirumotecan in EGFR-mutated Advanced NSCLC Patients With Positive ctDNA After lead-in Osimertinib Monotherapy | recruiting | Phase 2 | 120 | Guangdong Association of Clinical TrialsOTHER | 1 | May 26, 2026 | clinicaltrials |
| NCT03527108 | Nivolumab Plus Ramucirumab in Patients With Recurrent, Advanced, Metastatic NSCLC | active not recruiting | Phase 2 | 36 | Fox Chase Cancer CenterOTHER | 1 | May 22, 2026 | clinicaltrials |
| NCT03786692 | Phase II Randomized Trial of Carboplatin+Pemetrexed+Bevacizumab+/- Atezolizumab in Stage IV NSCLC | active not recruiting | Phase 2 | 107 | Fox Chase Cancer CenterOTHER | 1 | May 22, 2026 | clinicaltrials |
| NCT05800587 | Dose Attenuated Chemotherapy in Compromised Patients With Lung Cancer | recruiting | Phase 2 | 280 | Fox Chase Cancer CenterOTHER | 1 | May 22, 2026 | clinicaltrials |
| NCT06015503 | A Phase Ⅱ Study Assessing the Safety and Efficacy of PLB1004 in EGFR ex20ins Mutation Patients With Advanced and Metastatic Non-small Cell Lung Cancer(NSCLC)(KANNON) | active not recruiting | Phase 2 | 139 | Avistone Biotechnology Co., Ltd.INDUSTRY | 1 | May 22, 2026 | clinicaltrials |
| NCT06868849 | A Study of JMT203 in Patients With Cancer Cachexia | recruiting | Phase 1 / Phase 2 | 307 | Shanghai JMT-Bio Inc.INDUSTRY | 1 | May 22, 2026 | clinicaltrials |
| NCT07603661 | Sintilimab Plus Chemotherapy as Induction Therapy for Unresectable Stage IIIC NSCLC | not yet recruiting | Phase 2 | 33 | Sun Yat-sen UniversityOTHER | 0 | May 22, 2026 | clinicaltrials |
| NCT07603791 | Phase II Clinical Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Antitumor Activity of ALK202 for Injection in Combination With Drugs in NSCLC Participants. | not yet recruiting | Phase 2 | 252 | Shanghai Allink Biotherapeutics Co., Ltd.INDUSTRY | 0 | May 22, 2026 | clinicaltrials |
| NCT02696993 | Nivolumab and Radiation Therapy With or Without Ipilimumab in Treating Patients With Brain Metastases From Non-small Cell Lung Cancer | active not recruiting | Phase 1 / Phase 2 | 80 | M.D. Anderson Cancer CenterOTHER | 1 | May 20, 2026 | clinicaltrials |
| NCT04015778 | A Exploratory Study of Nivolumab Monotherapy or in Combination With Nab-paclitaxel and Carboplatin in Early Stage NSCLC in China | active not recruiting | Phase 2 | 316 | Guangdong Association of Clinical TrialsOTHER | 1 | May 20, 2026 | clinicaltrials |
| NCT05431270 | Dose Escalation/Expansion Study of Mavrostobart (PT199), an Anti-CD73 mAb, Administered Alone and in Combination With a PD-1 Inhibitor or Chemotherapy (the MORNINGSTAR Study) | recruiting | Phase 1 / Phase 2 | 40 | Phanes TherapeuticsINDUSTRY | 1 | May 19, 2026 | clinicaltrials |
| NCT07596121 | Serplulimab Monotherapy in Elderly Patients With NSCLC and PD-L1 TPS ≥ 50% | recruiting | Phase 2 | 60 | Tang-Du HospitalOTHER | 1 | May 19, 2026 | clinicaltrials |
| NCT03851445 | Lung-MAP: A Master Screening Protocol for Previously-Treated Non-Small Cell Lung Cancer | recruiting | Phase 2 / Phase 3 | 10,000 | SWOG Cancer Research NetworkNETWORK | 1 | May 18, 2026 | clinicaltrials |
| NCT05096663 | Testing the Use of Combination Immunotherapy Treatment (N-803 [ALT-803] Plus Pembrolizumab) Against the Usual Treatment for Advanced Non-small Cell Lung Cancer (A Lung-MAP Treatment Trial) | active not recruiting | Phase 2 / Phase 3 | 82 | SWOG Cancer Research NetworkNETWORK | 1 | May 18, 2026 | clinicaltrials |
| NCT06868836 | Phase II Clinical Study of JS207 (PD-1/VEGF Bispecific Antibody) Combination Therapies in Patients With Driver Gene-Positive, Advanced Non-Small Cell Lung Cancer After Failure of TKI Therapy | recruiting | Phase 2 | 78 | Shanghai Junshi Bioscience Co., Ltd.OTHER | 1 | May 18, 2026 | clinicaltrials |
| NCT07594522 | A Study of Ivonescimab in People With Non-Small Cell Lung Cancer | recruiting | Phase 1 / Phase 2 | 36 | Memorial Sloan Kettering Cancer CenterOTHER | 1 | May 18, 2026 | clinicaltrials |
| NCT05379985 | Study of RMC-6236 in Patients With Advanced Solid Tumors Harboring Specific Mutations in RAS | recruiting | Phase 1 / Phase 2 | 754 | Revolution Medicines, Inc.INDUSTRY | 1 | May 15, 2026 | clinicaltrials |
| NCT06606847 | A Study to Investigate the Effects of Durvalumab With Oleclumab Following Chemoradiation in Participants With Locally Advanced Unresectable Non-Small Cell Lung Cancer (LADOGA)(LADOGA) | active not recruiting | Phase 2 | 30 | AstraZenecaINDUSTRY | 1 | May 15, 2026 | clinicaltrials |
| NCT07332858 | First-in-Human Expanded Cohort Study of Intrapleural Administration of TolueneSulfonamide in Patients With Malignant Pleural Effusion | recruiting | Phase 1 / Phase 2 | 105 | Gang HouOTHER | 1 | May 15, 2026 | clinicaltrials |
| NCT04789486 | Nano-SMART: Nanoparticles With MR Guided SBRT in Centrally Located Lung Tumors and Pancreatic Cancer | recruiting | Phase 1 / Phase 2 | 100 | Dana-Farber Cancer InstituteOTHER | 1 | May 14, 2026 | clinicaltrials |
| NCT06922591 | Study to Evaluate the Safety, Tolerability & Efficacy of TNG462 in Combination in PDAC & NSCLC Patients | recruiting | Phase 1 / Phase 2 | 183 | Tango Therapeutics, Inc.INDUSTRY | 1 | May 14, 2026 | clinicaltrials |
| NCT06946797 | A Study to Evaluate Two Dosing Regimens of Subcutaneous Nivolumab in Combination With Intravenous Ipilimumab and Chemotherapy in Participants With Previously Untreated Metastatic or Recurrent Non-Small Cell Lung Cancer (NSCLC)(CheckMate-1533) | active not recruiting | Phase 2 | 76 | Bristol-Myers SquibbINDUSTRY | 9 | May 14, 2026 | clinicaltrials |
| NCT07216404 | Psilocybin-Assisted Therapy for the Treatment of Major Depressive Disorder in Patients With Non-Small Cell Lung Cancer | recruiting | Phase 2 | 10 | Alan DavisOTHER | 1 | May 14, 2026 | clinicaltrials |
| NCT07586826 | Romiplostim N01 Plus ATRA for Persistent Isolated Chemotherapy-Induced Thrombocytopenia After Complete Remission of Gynecologic, Breast, or Lung Solid Tumors(N01-A-PICIT-GT) | recruiting | Phase 2 | 220 | Peking University People's HospitalOTHER | 1 | May 14, 2026 | clinicaltrials |
| NCT07444437 | A Phase II Trial of LM103 for Adjuvant Treatment in Patients With Non-small Cell Lung Cancer | recruiting | Phase 2 | 45 | Suzhou BlueHorse Therapeutics Co., Ltd.INDUSTRY | 1 | May 13, 2026 | clinicaltrials |
| NCT07489716 | A Phase II Clinical Trial of SHR-1826 for Non-Small Cell Lung Cancer | recruiting | Phase 2 | 90 | Suzhou Suncadia Biopharmaceuticals Co., Ltd.INDUSTRY | 1 | May 13, 2026 | clinicaltrials |
| NCT05351788 | SKB264 Combinatiton Therapy in Patients With Advanced or Metastatic Non-small Cell Lung Cancer. | recruiting | Phase 2 | 110 | Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd.INDUSTRY | 1 | May 12, 2026 | clinicaltrials |
| NCT04716946 | Treating Early-stage Non-Small Cell Lung Cancer With Durvalumab and Radiation Therapy | active not recruiting | Phase 2 | 13 | Memorial Sloan Kettering Cancer CenterOTHER | 1 | May 11, 2026 | clinicaltrials |
| NCT03202940 | A Phase IB/II Study of Alectinib Combined With Cobimetinib in Advanced ALK-Rearranged (ALK+) NSCLC | active not recruiting | Phase 1 / Phase 2 | 16 | Massachusetts General HospitalOTHER | 1 | May 8, 2026 | clinicaltrials |
| NCT06195189 | Sunvozertinib Combined With Chemotherapy for EGFRm After EGFR-TKI Treatment Failure：Phase I/II(WU-KONG36) | recruiting | Phase 1 / Phase 2 | 40 | Sichuan UniversityOTHER | 1 | May 8, 2026 | clinicaltrials |
| NCT06380816 | A Phase I/II Trial of UCB4594 in Participants With Advanced Cancer | recruiting | Phase 1 / Phase 2 | 167 | Cancer Research UKOTHER | 1 | May 8, 2026 | clinicaltrials |
Data updated 23 days agoSource updated Jun 4, 2026source: clinicaltrials